Alkeon Capital Management LLC Acquires 1,495,736 Shares of Lam Research Corporation $LRCX

Key Points

• Alkeon Capital Management LLC increased its stake in Lam Research Corporation by 23.2%, acquiring 1,495,736 shares for a total holding of 7,954,456 shares, making it the firm's 10th largest position.
• Lam Research reported a 29.07% net margin and $5.17 billion in revenue for the recent quarter, surpassing expectations with an EPS of $1.33.
• The company recently announced a dividend increase, now set at $0.26 per share, reflecting an annualized dividend yield of 1.0%.

Alkeon Capital Management LLC lifted its holdings in Lam Research Corporation (NASDAQ:LRCX - Free Report) by 23.2% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,954,456 shares of the semiconductor company's stock after purchasing an additional 1,495,736 shares during the period. Lam Research comprises approximately 1.2% of Alkeon Capital Management LLC's holdings, making the stock its 10th biggest position. Alkeon Capital Management LLC owned approximately 0.62% of Lam Research worth $578,289,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of LRCX. Meridian Wealth Management LLC increased its position in Lam Research by 1.4% in the first quarter. Meridian Wealth Management LLC now owns 9,732 shares of the semiconductor company's stock worth $707,000 after purchasing an additional 130 shares during the last quarter. GW&K Investment Management LLC boosted its stake in Lam Research by 10.1% during the first quarter. GW&K Investment Management LLC now owns 1,534 shares of the semiconductor company's stock worth $112,000 after buying an additional 141 shares during the period. Dorsey & Whitney Trust CO LLC boosted its stake in Lam Research by 1.2% during the first quarter. Dorsey & Whitney Trust CO LLC now owns 12,498 shares of the semiconductor company's stock worth $909,000 after buying an additional 146 shares during the period. Citizens National Bank Trust Department boosted its stake in Lam Research by 34.0% during the first quarter. Citizens National Bank Trust Department now owns 603 shares of the semiconductor company's stock worth $44,000 after buying an additional 153 shares during the period. Finally, Progressive Investment Management Corp boosted its stake in Lam Research by 0.4% during the first quarter. Progressive Investment Management Corp now owns 42,581 shares of the semiconductor company's stock worth $3,096,000 after buying an additional 156 shares during the period. Institutional investors own 84.61% of the company's stock.

Wall Street Analysts Forecast Growth

LRCX has been the subject of several recent analyst reports. Wall Street Zen raised shares of Lam Research from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Stifel Nicolaus boosted their target price on shares of Lam Research from $92.00 to $110.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Wells Fargo & Company set a $98.00 target price on shares of Lam Research and gave the company an "equal weight" rating in a research note on Thursday, July 31st. Oppenheimer boosted their target price on shares of Lam Research from $110.00 to $120.00 and gave the company an "outperform" rating in a research note on Thursday, July 31st. Finally, Morgan Stanley restated an "underweight" rating and issued a $92.00 price objective (down from $94.00) on shares of Lam Research in a report on Tuesday. Twenty research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $107.22.

Lam Research Trading Up 2.5%

Shares of NASDAQ LRCX traded up $2.53 during trading on Friday, hitting $102.95. 8,138,513 shares of the company were exchanged, compared to its average volume of 10,784,377. Lam Research Corporation has a 12-month low of $56.32 and a 12-month high of $108.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.55 and a current ratio of 2.21. The company has a fifty day moving average price of $99.87 and a 200-day moving average price of $85.83. The firm has a market capitalization of $130.30 billion, a PE ratio of 24.75, a P/E/G ratio of 1.29 and a beta of 1.76.

Lam Research (NASDAQ:LRCX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The semiconductor company reported $1.33 EPS for the quarter, topping the consensus estimate of $1.21 by $0.12. The business had revenue of $5.17 billion for the quarter, compared to analyst estimates of $4.99 billion. Lam Research had a return on equity of 58.17% and a net margin of 29.07%.The company's quarterly revenue was up 33.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.03 EPS. Lam Research has set its Q1 2026 guidance at 1.100-1.300 EPS. As a group, equities research analysts expect that Lam Research Corporation will post 3.71 EPS for the current year.

Lam Research Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Wednesday, September 24th will be given a $0.26 dividend. The ex-dividend date of this dividend is Wednesday, September 24th. This represents a $1.04 annualized dividend and a yield of 1.0%. This is an increase from Lam Research's previous quarterly dividend of $0.23. Lam Research's dividend payout ratio is presently 22.12%.

About Lam Research

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.